Five-year outcomes from the DESSOLVE I and II trials published December 26, 2017 in the journal EuroIntervention show the long-term safety and effectiveness of a sirolimus-eluting stent (MiStent SES) with a bioabsorbable coating with low rates of five-year major adverse cardiac events (MACE), target lesion failure (TLF) and target vessel failure (TVF). No stent thrombosis was reported with the MiStent in both the trials.